[{"id":"6327dec6-05f5-4a23-9177-c88c3db8f2ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT06951399","created_at":"2025-07-26T13:31:06.459Z","updated_at":"2025-07-26T13:31:06.459Z","phase":"Phase 2","brief_title":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06951399","lead_sponsor":"Rabin Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2025-07-22"},{"id":"c3548fdd-4823-401f-9549-b60f0636a1a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06953492","created_at":"2025-09-07T01:27:35.276Z","updated_at":"2025-09-07T01:27:35.276Z","phase":"","brief_title":"Sleep State in Lung Cancer: A Retrospective Analysis","source_id_and_acronym":"NCT06953492","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Completed","enrollment":" Enrollment 300","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2025-05-01"},{"id":"8938bf1a-b3df-4fc1-a9f9-c9727dc17f53","acronym":"","url":"https://clinicaltrials.gov/study/NCT06843629","created_at":"2025-02-27T07:06:33.229Z","updated_at":"2025-02-27T07:06:33.229Z","phase":"","brief_title":"Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors","source_id_and_acronym":"NCT06843629","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-25"},{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"be73eee7-8633-483e-a581-812fd81e01b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929041","created_at":"2021-06-18T23:52:29.992Z","updated_at":"2025-02-25T14:02:22.824Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","source_id_and_acronym":"NCT04929041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 427","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"e6419ea6-12ef-460f-8597-b07958498262","acronym":"IMMUNOMEK","url":"https://clinicaltrials.gov/study/NCT05937906","created_at":"2023-07-10T13:08:51.069Z","updated_at":"2025-02-25T14:09:51.533Z","phase":"Phase 1/2","brief_title":"Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 \u003c 50 %.","source_id_and_acronym":"NCT05937906 - IMMUNOMEK","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Gomekli (mirdametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/30/2024","start_date":" 07/30/2024","primary_txt":" Primary completion: 05/25/2028","primary_completion_date":" 05/25/2028","study_txt":" Completion: 05/25/2028","study_completion_date":" 05/25/2028","last_update_posted":"2025-02-18"},{"id":"442d5c06-75a4-48d9-85ea-9b9fc557a2ef","acronym":"INSIGHT","url":"https://clinicaltrials.gov/study/NCT03252938","created_at":"2021-01-17T17:46:57.179Z","updated_at":"2025-02-25T15:10:38.137Z","phase":"Phase 1","brief_title":"Feasibility and Safety of IMP321 (eftilagimod Alpha) for Advanced Stage Solid Tumors","source_id_and_acronym":"NCT03252938 - INSIGHT","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • ImmuFact (eftilagimod alpha)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 08/15/2017","start_date":" 08/15/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-13"},{"id":"9518cf2f-a488-48b8-a437-c584bd916e0c","acronym":"Brightline-2","url":"https://clinicaltrials.gov/study/NCT05512377","created_at":"2022-08-23T14:55:35.585Z","updated_at":"2025-02-25T15:19:58.742Z","phase":"Phase 2","brief_title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","source_id_and_acronym":"NCT05512377 - Brightline-2","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2025-02-11"},{"id":"aef3f3cb-aa50-40d2-b1b1-727aae5c68fd","acronym":"CHRYSALIS","url":"https://clinicaltrials.gov/study/NCT02609776","created_at":"2021-01-17T17:17:24.122Z","updated_at":"2025-02-25T15:33:33.328Z","phase":"Phase 1","brief_title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02609776 - CHRYSALIS","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 751","initiation":"Initiation: 05/24/2016","start_date":" 05/24/2016","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-11"},{"id":"c0529000-1eea-42c3-9cae-d983a7189b6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05943795","created_at":"2023-07-13T18:10:45.267Z","updated_at":"2025-02-25T15:36:23.229Z","phase":"Phase 3","brief_title":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","source_id_and_acronym":"NCT05943795","lead_sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • izalontamab (SI-B001)"],"overall_status":"Recruiting","enrollment":" Enrollment 584","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-11"},{"id":"2e65ab02-5455-476f-a9fc-8810d776844a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01386385","created_at":"2021-01-19T08:29:02.253Z","updated_at":"2025-02-25T16:36:10.447Z","phase":"Phase 1/2","brief_title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01386385","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ERCC1 • XRCC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 05/26/2019","primary_completion_date":" 05/26/2019","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"73e8506b-a82d-41df-b4ff-414021e9babc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03042221","created_at":"2021-01-18T14:58:44.313Z","updated_at":"2025-02-25T16:36:51.399Z","phase":"","brief_title":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","source_id_and_acronym":"NCT03042221","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRAF • ALK • ROS1 • CD8 • CDH1 • CD14 • VIM • MRC1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • ROS1 fusion","tags":["BRAF • ALK • ROS1 • CD8 • CDH1 • CD14 • VIM • MRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • ROS1 fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/10/2016","start_date":" 05/10/2016","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"d3bd037a-496e-40a7-bdf6-271632f38a73","acronym":"C4391001","url":"https://clinicaltrials.gov/study/NCT04557449","created_at":"2021-01-18T21:47:02.862Z","updated_at":"2025-02-25T16:45:10.545Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","source_id_and_acronym":"NCT04557449 - C4391001","lead_sponsor":"Pfizer","biomarkers":" CDKN2A • CCND1 • CD4","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["CDKN2A • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • fulvestrant • letrozole • atirmociclib (PF-07220060) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 09/23/2026","primary_completion_date":" 09/23/2026","study_txt":" Completion: 11/23/2027","study_completion_date":" 11/23/2027","last_update_posted":"2025-02-05"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"babb040a-8e58-46a5-a8a3-a326e81d8c49","acronym":"MORAb-202-G000-201","url":"https://clinicaltrials.gov/study/NCT04300556","created_at":"2021-01-18T20:51:39.021Z","updated_at":"2025-02-25T14:29:08.502Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","source_id_and_acronym":"NCT04300556 - MORAb-202-G000-201","lead_sponsor":"Eisai Inc.","biomarkers":" HER-2 • BRAF • ER • ALK • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRAF • ER • ALK • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • prednisone • dexamethasone • farletuzumab ecteribulin (MORAb-202) • farletuzumab (MORAB-003) • prednisolone"],"overall_status":"Recruiting","enrollment":" Enrollment 142","initiation":"Initiation: 08/06/2020","start_date":" 08/06/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-12-09"},{"id":"cadb8f0d-9482-4575-b4e2-ae2b496d1ae5","acronym":"U31402-A-U102","url":"https://clinicaltrials.gov/study/NCT03260491","created_at":"2021-01-17T17:11:50.865Z","updated_at":"2025-02-25T16:06:47.472Z","phase":"Phase 1","brief_title":"U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03260491 - U31402-A-U102","lead_sponsor":"Daiichi Sankyo","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 309","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-11-22"},{"id":"42c51771-6ced-4902-9fd0-2fa649ac3732","acronym":"TranStar102","url":"https://clinicaltrials.gov/study/NCT04495296","created_at":"2021-01-18T21:32:44.326Z","updated_at":"2025-02-25T14:29:29.560Z","phase":"Phase 1/2","brief_title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04495296 - TranStar102","lead_sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • paclitaxel • capecitabine • oxaliplatin • osemitamab (TST001)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/13/2020","start_date":" 08/13/2020","primary_txt":" Primary completion: 02/25/2025","primary_completion_date":" 02/25/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-21"},{"id":"d82a221e-2215-4347-8758-157582bc7fc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06619886","created_at":"2025-02-26T15:00:04.363Z","updated_at":"2025-02-26T15:00:04.363Z","phase":"Phase 1","brief_title":"TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor","source_id_and_acronym":"NCT06619886","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" TP53","pipe":"","alterations":" ","tags":["TP53"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 09/24/2024","start_date":" 09/24/2024","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-10-01"},{"id":"0b5f1810-21e0-4d81-99c2-2da131cdd433","acronym":"VISION","url":"https://clinicaltrials.gov/study/NCT02864992","created_at":"2021-01-17T17:11:42.537Z","updated_at":"2025-02-25T16:05:05.696Z","phase":"Phase 2","brief_title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","source_id_and_acronym":"NCT02864992 - VISION","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tepmetko (tepotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 337","initiation":"Initiation: 09/13/2016","start_date":" 09/13/2016","primary_txt":" Primary completion: 05/16/2022","primary_completion_date":" 05/16/2022","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-08-30"},{"id":"784231b9-195e-4cdb-8b0c-3f60c54cd03b","acronym":"KEYNOTE-098","url":"https://clinicaltrials.gov/study/NCT02443324","created_at":"2021-01-17T17:34:42.987Z","updated_at":"2025-02-25T16:14:44.151Z","phase":"Phase 1","brief_title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","source_id_and_acronym":"NCT02443324 - KEYNOTE-098","lead_sponsor":"Eli Lilly and Company","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 175","initiation":"Initiation: 07/29/2015","start_date":" 07/29/2015","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 04/12/2022","study_completion_date":" 04/12/2022","last_update_posted":"2024-07-31"},{"id":"f9f357c2-8949-408a-8e82-24a82b424f06","acronym":"EVER-132-003","url":"https://clinicaltrials.gov/study/NCT05119907","created_at":"2023-03-03T17:01:47.232Z","updated_at":"2024-07-02T16:34:25.825Z","phase":"Phase 2","brief_title":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","source_id_and_acronym":"NCT05119907 - EVER-132-003","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/12/2021","start_date":" 10/12/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"58c1e0c0-b674-448a-ae94-6a539accdd99","acronym":"","url":"https://clinicaltrials.gov/study/NCT05198830","created_at":"2022-01-20T15:53:52.796Z","updated_at":"2024-07-02T16:34:26.376Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05198830","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • Pemfexy (pemetrexed) • methoxyamine (TRC102)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-13"}]